drugset / Trial / NCT02426372
Safety and Efficacy of QBECO in Moderate to Severe Ulcerative Colitis
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this open-label, dose-ranging, exploratory study is to evaluate the safety, tolerability, compliance, mechanism of action and efficacy of QBECO site specific immunomodulation for the induction of clinical response and remission in subjects with moderate to severe ulcerative colitis
Timeline
- Start
- 2015-07
- Primary completion
- 2016-12
- Completion
- 2016-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | QBECO SSI | Unknown | 0.02 ml | Subcutaneous |
| Subject | QBECO SSI | Unknown | 0.05 ml | Subcutaneous |
| Subject | QBECO SSI | Unknown | 0.1 ml | Subcutaneous |